Gan and Lee Pharmaceuticals (SHSE:603087) ROCE %: 16.58% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603087 Gan and Lee Pharmaceuticals SHSE:603087
90 GF Score
Price ¥66.34
GF Value ¥73.00
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Gan and Lee Pharmaceuticals ROCE %?

Gan and Lee Pharmaceuticals SHSE:603087 -2.27% 90 ROCE % is 16.58% as of Jun. 2026. GuruFocus rates SHSE:603087 with a GF Score™ of 90/100 and a GF Value™ of ¥73.00 (Fairly Valued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Gan and Lee Pharmaceuticals's annualized ROCE % for the quarter that ended in Jun. 2026 was 16.58%.

Gan and Lee Pharmaceuticals  (SHSE:603087) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Gan and Lee Pharmaceuticals ROCE % Related Terms

Gan and Lee Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Gan and Lee Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gan and Lee Pharmaceuticals ROCE % Chart

Gan and Lee Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.42 -5.77 2.96 5.69 10.67

Gan and Lee Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.46 1.21 17.36 6.44 16.58
SHSE:603087
90GF Score
Gan and Lee Pharmaceuticals SHSE:603087
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gan and Lee Pharmaceuticals ROCE % Calculation

Gan and Lee Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=1230.037/( ( (12042.916 - 801.132) + (12627.043 - 815.787) )/ 2 )
=1230.037/( (11241.784+11811.256)/ 2 )
=1230.037/11526.52
=10.67 %

Gan and Lee Pharmaceuticals's ROCE % of for the quarter that ended in Jun. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=1982.128/( ( (12679.783 - 676.526) + (12762.003 - 853.374) )/ 2 )
=1982.128/( ( 12003.257 + 11908.629 )/ 2 )
=1982.128/11955.943
=16.58 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 16.58% mean?
Gan and Lee Pharmaceuticals (SHSE:603087) has a ROCE % of 16.58% as of Jun. 2026.
Is Gan and Lee Pharmaceuticals' ROCE % too high?
Gan and Lee Pharmaceuticals' current ROCE % is 16.58%. The Medical Devices & Instruments industry median ROCE % is 2.97. Gan and Lee Pharmaceuticals' value of 16.58% is 458.2% above this industry median. Overall, Gan and Lee Pharmaceuticals has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gan and Lee Pharmaceuticals' ROCE % compare to ISRG and BDX?
Gan and Lee Pharmaceuticals' ROCE % of 16.58% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.97. Gan and Lee Pharmaceuticals' value of 16.58% is 458.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.97, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gan and Lee Pharmaceuticals's current ROCE % of 16.58% is 458.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gan and Lee Pharmaceuticals's current ROCE % is 16.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gan and Lee Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Gan and Lee Pharmaceuticals (SHSE:603087) is currently considered Fairly Valued. The stock's GF Value™ is ¥73.00, compared to a current price of ¥66.34 — trading 9.1% below its estimated fair value. The current ROCE % is 16.58% and 458.2% above the Medical Devices & Instruments industry median of 2.97. Gan and Lee Pharmaceuticals' overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Gan and Lee Pharmaceuticals (SHSE:603087), the current ROCE % is 16.58% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gan and Lee Pharmaceuticals (SHSE:603087) Overvalued in 2026?

Based on GuruFocus' analysis, Gan and Lee Pharmaceuticals stock appears to be undervalued. The current stock price of ¥66.34 is trading 9.1% below its estimated GF Value™ of ¥73.00. GuruFocus considers Gan and Lee Pharmaceuticals to be Fairly Valued.

Key valuation signals for SHSE:603087:

  • ROCE %: 16.58%
  • GF Value™: ¥73.00 vs. price of ¥66.34 (9.1% below fair value)
  • GF Score™: 90/100 with 5 warning signs
  • Industry Position: 458.2% above the Medical Devices & Instruments median

No single metric tells the full story. See the SHSE:603087 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gan and Lee Pharmaceuticals Business Description

Address No. 8, Nanfengxi 1st Road, Xianxian Town, Tongzhou District, Beijing, CHN, 101109
Gan and Lee Pharmaceuticals is engaged in Research, development, production and sales of recombinant insulin analog APIs and injections.
90GF Score

Get the complete analysis for SHSE:603087

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥66.34
Price
¥73.00
GF Value